Clinical trial
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
NCT00111137 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111137 |
|---|---|
| Title | Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy |
| Official title | A Randomized, Open Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients With Non-Myeloid Malignancies Receiving Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer, Non-Myeloid Malignancies |
| Intervention type | Drug |
| Interventions | rHuEPO, Darbepoetin alfa |
| Enrollment | 718 |
| Start date | Feb 1, 2003 |
| Primary completion | Nov 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | May 18, 2005 |
| Last update posted | Feb 28, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: